Antibody molecules that bind CD137 and OX40
US12252537B2 · kind B2 · utility
0Cited by
20References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2019 |
| Grant date | Mar 18, 2025 |
| Priority date | — |
| Expiry date | Feb 20, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application relates to antibody molecules that bind and am able to agonise both CD137 and OX40. The antibody molecules comprise a CDR-based binding site for CD137, and an OX40 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer and infectious diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.